Standalone Audited Financial Results for the Quarter ended & Year ended on March 31, 2026 along with statement of Assets & Liabilities, Cash Flow statement & unmodified Audit Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rekvina Laboratories Ltd reported revenue from operations of Rs. 126.54 lakhs for FY26, up 7.09% from Rs. 118.16 lakhs in FY25. The company swung to profit after tax of Rs. 4.28 lakhs from a loss of Rs. 4.28 lakhs in the previous year, representing a significant turnaround. Profit before tax improved marginally from Rs. 3.35 lakhs to Rs. 4.30 lakhs. EPS stood at Rs. 0.07 per share (both basic and diluted). The statutory auditor Y. M. Shah & Co. issued an unmodified opinion on the annual financial results. Additionally, the Board approved a 100% equity acquisition of Nanoani Laboratories Ltd for Rs. 4,62,77,500 via share exchange, and a share subscription agreement for issuing 10,00,000 equity shares to Amitkumar Arunkumar Rao and Amitkumar Arjunbhai for Rs. 1,46,00,000.
The company returned to profitability after a loss-making FY25, though revenue growth remains modest at 7%. The upcoming acquisition of Nanoani Laboratories and preferential share issuance suggest strategic expansion plans that could reshape the company's business profile.